RxDoctor Payments Data

Dexter Jacob, MD

Interventional Cardiology · East Norriton, PANPI 1306112644

Payments from drug & device makers

$1,198in general payments, 2019–2025

Across 38 payments — averaging $31.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Philips North America LLC$186
  • Medtronic$185
  • Bard Peripheral Vascular, Inc.$171
  • Boston Scientific$149
  • Edwards Lifesciences$115
  • Novartis$77
  • plus $316 from 11 others

What the payments were for

  • Food & beverage$1,198100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,198 in reported general payments places this provider in the 10th percentile of 281 interventional cardiology providers in Pennsylvania.

See all interventional cardiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$645,820
Medicare patients
860
Services billed
3,534

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban161$164,074
EntrestoSacubitril/Valsartan48$60,027
XareltoRivaroxaban33$39,234
Repatha SureclickEvolocumab25$32,170
JardianceEmpagliflozin19$24,145
VascepaIcosapent Ethyl17$12,537
FarxigaDapagliflozin Propanediol11$12,264
Icosapent Ethyl17$7,115
Atorvastatin Calcium400$6,966
Praluent PenAlirocumab13$6,207
Ezetimibe165$5,442
Metoprolol Succinate332$5,121
Rosuvastatin Calcium229$4,760
Valsartan106$3,392
Flecainide Acetate28$2,329

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$49$164,074161 claims
NovartisEntresto$77$60,02748 claims
Johnson & JohnsonXarelto$48$39,23433 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 281 interventional cardiology providers in Pennsylvania.

Other interventional cardiology in East Norriton

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →